Literature DB >> 3308343

A controlled trial of ambroxol in chronic bronchitis.

G H Guyatt1, M Townsend, F Kazim, M T Newhouse.   

Abstract

Ambroxol is a mucolytic agent which is widely used in chronic bronchitis in Europe. We conducted a double-blind randomized controlled trial of ambroxol vs matched placebo in 90 patients with chronic bronchitis and difficulty clearing secretions. It was concluded that there was no advantage to taking ambroxol.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3308343     DOI： 10.1378/chest.92.4.618

Source DB:  PubMed          Journal:  Chest        ISSN： 0012-3692            Impact factor:   9.410


  12 in total

Review 1.  [Good sense and nonsense of antitussive agents].

Authors:  A Gillissen; S Tasci; S Ewig; H Schäfer; S Zielen
Journal:  Internist (Berl)       Date:  2001-01       Impact factor: 0.743

2.  Drug utilization in general practice: prescribing habits of National Formulary drugs by GPs of Emilia Romagna (Italy) in 1988 and 1989.

Authors:  N Montanaro; N Magrini; A Vaccheri; M Battilana
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 3.  Management of chronic obstructive pulmonary disease.

Authors:  S Kesten; A S Rebuck
Journal:  Drugs       Date:  1989-07       Impact factor: 9.546

4.  Ambroxol - Resurgence of an old molecule as an anti-inflammatory agent in chronic obstructive airway diseases.

Authors:  P R Gupta
Journal:  Lung India       Date:  2010-04

Review 5.  Appropriate use of antitussives and protussives. A practical review.

Authors:  R S Irwin; F J Curley; F M Bennett
Journal:  Drugs       Date:  1993-07       Impact factor: 9.546

6.  Guidelines for the assessment and management of chronic obstructive pulmonary disease. Canadian Thoracic Society Workshop Group.

Authors: 
Journal:  CMAJ       Date:  1992-08-15       Impact factor: 8.262

7.  [Chronic obstructive pulmonary disease : new pharmacotherapeutic options].

Authors:  T Greulich; A R Koczulla; C Vogelmeier
Journal:  Internist (Berl)       Date:  2012-11       Impact factor: 0.743

8.  Tools for assessing outcomes in studies of chronic cough: CHEST guideline and expert panel report.

Authors:  Louis-Philippe Boulet; Remy R Coeytaux; Douglas C McCrory; Cynthia T French; Anne B Chang; Surinder S Birring; Jaclyn Smith; Rebecca L Diekemper; Bruce Rubin; Richard S Irwin
Journal:  Chest       Date:  2015-03       Impact factor: 9.410

9.  Enhanced Controlled Transdermal Delivery of Ambroxol from the EVA Matrix.

Authors:  C W Cho; D B Kim; H W Cho; S C Shin
Journal:  Indian J Pharm Sci       Date:  2012-03       Impact factor: 0.975

10.  Bacterial lysate in the prevention of acute exacerbation of COPD and in respiratory recurrent infections.

Authors:  F Braido; F Tarantini; V Ghiglione; G Melioli; G W Canonica
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2007
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.